Cargando…

KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary

Detalles Bibliográficos
Autores principales:	Vauthey, J-N, Kopetz, S, Aloia, T A, Andreou, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494431/ https://www.ncbi.nlm.nih.gov/pubmed/23018559 http://dx.doi.org/10.1038/bjc.2012.419

Ejemplares similares

Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary
por: Yoshino, T, et al.
Publicado: (2012)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
por: Zocche, David M., et al.
Publicado: (2015)

Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX
por: Park, Hye Eun, et al.
Publicado: (2021)

Association between KRAS mutation and lung metastasis in advanced colorectal cancer
por: Pereira, A A L, et al.
Publicado: (2015)

Comment on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’
por: Normanno, N, et al.
Publicado: (2012)

Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
por: Spindler, K-L G, et al.
Publicado: (2014)

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
por: Nguyen, T. Quang, et al.
Publicado: (2019)

Folfox encephalopathy: A rare case series
por: Batra, Ullas, et al.
Publicado: (2017)

Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
por: Tougeron, D, et al.
Publicado: (2014)

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
por: Fiore, F Di, et al.
Publicado: (2008)

Oncogenic Kras drives invasion and maintains metastases in colorectal cancer
por: Boutin, Adam T., et al.
Publicado: (2017)

KRAS Transitions and Villous Growth in Colorectal Adenomas
por: Risio, Mauro, et al.
Publicado: (2005)

Prevotella contributes to individual response of FOLFOX in colon cancer
por: Hou, Xiao‐Ying, et al.
Publicado: (2021)

BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers
por: Khan, Sajid, et al.
Publicado: (2022)

Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients
por: Pathak, Surajit, et al.
Publicado: (2017)

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition
por: Rouleau, E, et al.
Publicado: (2008)

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
por: Bertolini, F, et al.
Publicado: (2011)

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy
por: Harada, Kazuaki, et al.
Publicado: (2019)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
por: Park, Dawon, et al.
Publicado: (2018)

KRAS mutation in lung metastases from colorectal cancer: prognostic implications
por: Ghidini, Michele, et al.
Publicado: (2015)

Adjuvant treatment in colorectal cancer
por: Taal, B G, et al.
Publicado: (2002)

Comment on ‘The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome': Intraperitoneal FOLFOX does not consistently induce sinusoidal obstruction syndrome in C57BL/6 mice
por: Lentschener, Claude, et al.
Publicado: (2016)

Reply to comment by Normanno et al on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’
por: de Castro, D G, et al.
Publicado: (2012)

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
por: Fakih, Marwan, et al.
Publicado: (2022)

Response to 'Comment on 'The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome''
por: Robinson, S M, et al.
Publicado: (2016)

Reply to comments on “Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei”
por: Hiraide, Sakura, et al.
Publicado: (2021)

The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma
por: Chang, Kuang-Leei, et al.
Publicado: (2016)

Perioperative FOLFOX in management of peritoneal metastases of colorectal cancer. Case report of 2 patients
por: Sugarbaker, Paul H., et al.
Publicado: (2020)

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
por: Knijn, N, et al.
Publicado: (2011)

Global Proteome Changes in Liver Tissue 6 Weeks after FOLFOX Treatment of Colorectal Cancer Liver Metastases
por: Urdzik, Jozef, et al.
Publicado: (2016)

Identification of Somatic KRAS Mutation in a Korean Baby with Nevus Sebaceus Syndrome
por: Kim, Sung Woo, et al.
Publicado: (2015)

KRAS, KIT and TP53 mutations in mother’s and daughter’s gastric cardia adenocarcinomas
por: Gluszek, Stanislaw, et al.
Publicado: (2018)

KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis
por: Cejas, Paloma, et al.
Publicado: (2009)

Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases
por: Shady, Waleed, et al.
Publicado: (2017)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
por: Choughule, A, et al.
Publicado: (2014)

Primary Regressive, But Metastasizing Melanoma!?
por: Tchernev, Georgi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c4i9kqopvb3o5v7qec01m9cdo4